RIS Rx Appoints Leslie Donato to Board of Directors

Audio By Carbonatix

IRVINE, Calif.--(BUSINESS WIRE)--Dec 22, 2025--

RIS Rx, a healthcare technology company offering gross-to-net (GTN) revenue protection and saving more than $1 billion for the world’s leading pharmaceutical manufacturers, today announced the appointment of Leslie Donato to its Board of Directors.

Ms. Donato is a highly accomplished healthcare executive with more than 30 years of experience in corporate strategy, commercialization, and enterprise growth. Most recently, she served as Executive Vice President and Chief Strategy Officer at Cencora, where she played a vital role in shaping the company’s strategic direction, leading transformative M&A activity and contributing to a 130% increase in the company’s market capitalization over five years. Prior to Cencora, Ms. Donato held leadership positions at Bayer Healthcare Pharmaceuticals and spent 14 years as a Principal in McKinsey & Company’s Pharmaceutical & Medical Products Practice. She serves on the boards of multiple healthcare and life sciences organizations including Keenova Therapeutics, COPILOT Provider Support Services and Virtua Health, bringing broad expertise in strategic planning, corporate development and commercialization.

“Leslie brings an incredible depth of experience and strategic insight to RIS Rx," said Gerard Rivera, CEO and Co-Founder of RIS Rx. “Her experience in driving growth, navigating complex markets and leading cross-functional teams will greatly enhance our board’s capabilities as we continue to expand our impact in the pharmaceutical ecosystem.”

“I’m delighted to join the RIS Rx Board of Directors,” said Leslie Donato. “The company’s innovative approach to addressing persistent challenges in the GTN process is unrivalled, and I look forward to collaborating with Gerard and the board to support RIS Rx’s continued success in improving outcomes for patients and manufacturers alike.”

About RIS Rx

RIS Rx is a healthcare technology company delivering gross-to-net (GTN) revenue protection for the world’s leading pharmaceutical manufacturers. Through proprietary software, real-time analytics and pharmacist-led expertise, RIS Rx helps clients optimize operations, eliminate leakage and ensure that financial assistance reaches the patients who need it most. In 2025 alone, the company has protected more than $1 billion in revenue for its customers. Founded in 2020 and headquartered in Irvine, California, RIS Rx serves leading pharmaceutical manufacturers across a growing portfolio of drug brands. Learn more at www.RISRx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251222647098/en/

CONTACT: Media:

Chase Carpenter

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH TECHNOLOGY HEALTH TECHNOLOGY SOFTWARE PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: RIS Rx

Copyright Business Wire 2025.

PUB: 12/22/2025 10:00 AM/DISC: 12/22/2025 10:00 AM

http://www.businesswire.com/news/home/20251222647098/en